Goedgekeurd onderzoek
Hieronder vindt u een lijst met GIANTT-onderzoek dat is goedgekeurd door de Stuurgroep en momenteel loopt:
Overview of approved GIANTT studies
| Year | Number | Title | Applicant | Status |
|---|---|---|---|---|
| 2016 | 33 | HbA1c trajectories after initiation of insulin in patients with diabetes | Grigory Sidorenkov | Published |
| 2017 | 35 | Prescription trends of novel glucose regulating medication in type 2 diabetes in the Northern part of the Netherlands | Klaas Hoogenberg | Searching for funding |
| 2017 | 36 | Type 2 diabetes treatment in the elderly: trends in the era of implementing age-dependent targets | Klaas Hoogenberg | Published |
| 2017 | 37 | Population based screening compared to opportunistic screening for type 2 diabetes: comparable medication needs? | Rimke Vos | Published |
| 2017 | 38 | The role of differences in drug prescribing (e.g. drug selection, dosing, comedication) in relation to sex differences in adverse drug reactions in people with type 2 diabetes | Sieta de Vries | Published |
| 2018 | 39 | Decreasing hypoglycaemia risk in type 2 diabetes: Identifying patients at high risk | Stijn Crutzen | Published |
| 2020 | 40 | Adverse events in relation to systolic blood pressure levels and antihypertensive treatment according to sex, age and frailty | Martina Ambroz | Published |
| 2020 | 41 | Differences during the life course in the lipid spectrum between men and women with type 2 diabetes and the effect on it of statins | Sieta de Vries | Published |
| 2020 | 42 | Sex differences in treatment decisions and effects in type 2 diabetes patients | Monik Oktora | Published |
| 2020 | 43 | The Impact of Sex on Quality of Medication Treatment in Patients with Type 2 Diabetes | Marit Geelink | Published |
| 2021 | 44 | Identifying risk factors for breast cancer susceptibility in women with pre-existing type 2 diabetes mellitus based on a Dutch population | Grigory Sidorenkov | Published |
| 2021 | 45 | Relationship between triglyceride/HDL-cholesterol ratio, glucose-lowering medication and cardiovascular disease in people with type 2 diabetes | Fieke Teerstra | Study halted |
| 2023 | 46 | The potential value of the intensive treat-to-target statin therapy in the Netherlands | Anjali Hood | Completed Master Thesis |
| 2023 | 47 | Cost-effectiveness evaluation of additional treatment with SGLT2 inhibitors on diabetic nephropathy outcomes | Ngoc Thuy Tram Nguyen | Completed Master Thesis |
| 2024 | 48 | Representativeness of people with diabetes who participate in research on reducing and stopping their medication | Petra Denig | Completed Bachelor Thesis |